The Sharifi Lab

The Sharifi lab is focused on identifying molecular mechanisms of targeted therapy resistance in advanced breast and prostate cancer to develop new and more effective therapies. Our research utilizes translational liquid biopsy based approaches and patient derived models to evaluate dynamic changes in endocrine and oncogene signaling that occur in response to endocrine, PI3K pathway, and cell surface targeted therapies in patients with hormone dependent cancers. The overarching goal of our work is to develop new strategies to overcome targeted therapy resistance through a better understanding of the molecular changes that drive resistance in patients.